Thinking of joining a study?

Register your interest

Become a volunteer?

NCT03753243 | RECRUITING | Prostate Cancer

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Sponsor:

Mark Garzotto, MD

Information provided by (Responsible Party):

Mark Garzotto, MD

Brief Summary:

Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day. All patients will be required to have at least one high-risk criteria.

Condition or disease

Prostate Cancer

Intervention/treatment

Pembrolizumab

Enzalutamide

Phase

PHASE2

Detailed Description:

The investigators propose to study the effects of pembrolizumab combined with intensive androgen receptor (AR) targeting prior to prostatectomy with extended pelvic lymph node dissection in subjects with high-risk localized prostate cancer (HRLPC). Trial Design- single arm, single-stage, open label Phase II of neoadjuvant immune-hormonal therapy in high-risk localized prostate cancer. Objectives To evaluate efficacy and safety of pembrolizumab combined with intensive AR targeting prior to prostatectomy in subjects with high-risk localized prostate cancer (HRLPC). Primary Endpoint Pathologic complete response (pCR) defined as absence of detectable malignant cells in the prostatectomy specimen evaluated by standard histologic techniques.

Study Type : INTERVENTIONAL
Estimated Enrollment : 32 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Actual Study Start Date : 2018-12-03
Estimated Primary Completion Date : 2022-09-03
Estimated Study Completion Date : 2023-04-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Be willing and able to provide written informed consent/assent for the trial.
  • * Capability to understand and comply with the protocol and signed informed consent document.
  • * Be ≥ 18 years of age on day of signing informed consent.
  • * Have measurable disease based on RECIST 1.1.
  • * Histologically confirmed, non-metastatic adenocarcinoma of the prostate
  • * Prostatectomy with extended lymph node dissection planned as primary therapy
  • * 10 year or longer life expectancy based on other co-morbidities
  • * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
  • * Any one of the following three high risk features
    • * Gleason grade \> 8-10
    • * PSA \> 20 ng/ml
    • * Clinical stage T3a (resectable)
    • * No evidence of metastases .
    • * No other diagnosis of malignancy (with exception of non-melanoma skin cancer or a malignancy diagnosed ≥5 years ago).
    • * Male subjects of childbearing potential must agree to use an adequate method of contraception. Contraception, starting with the first dose of study therapy through the time of surgery. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
    • * Demonstrate adequate organ function, all screening labs should be performed within 30 days of treatment initiation.
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Location Details

NCT03753243

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Oregon

VA Portland Healthcare System

Portland, Oregon, United States, 97239